Factors associated with improved progression-free survival were methylated MGMT (HR = 0.47, 95% CI 0.33–0.66, p < 0.001) as well as having no contrast-enhancing residual tumour (compared with biopsy) (HR = 0.59, 95% CI 0.36–0.96, p = 0.04) or non-measurable contrast-enhancing residual tumour (compared with biopsy) (HR = 0.53, 95% CI 0.33–0.86, p = 0.01). Here, MGMT is linked to neoplasm.